DOCSLIB.ORG

Autophagy: from Membrane Movement to Nuclear Regulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Autophagy: From Membrane Movement to Nuclear Regulation by Melinda Anne Lynch Day A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Molecular, Cellular and Developmental Biology) in The University of Michigan 2012 Doctoral Committee: Professor Daniel J. Klionsky, Chair Professor Laura J. Olsen Professor Lois S. Weisman Associate Professor Anuj Kumar © Melinda Anne Lynch Day 2012 In Memory of Geoff Whose death drove my desire to study biology, but whose life inspires me to live with conviction and passion. ii Acknowledgements I would first like to thank my wonderful husband, Dave, who has been patiently waiting for me to finish my doctoral studies. His love and encouragement have helped carry me through the last five years. I would also like to thank my parents, whose help has been invaluable. Thank you for teaching me the value of hard work. Appreciation is also due to others of my family including my in-laws and my aunt and uncle, all of whom have provided encouragement through it all. A special thank you is owed to my advisor, Dan Klionsky. He has been a wonderful mentor and has taught me the critical thinking skills needed to become an independent scientist. He challenged me and encouraged me, and I couldn’t have asked for a better mentor. I would also like to thank my committee members, Lois Weisman, Laura Olsen, and Anuj Kumar. Thank you all for your patience and your invaluable advice. I am grateful for all of your support in working with me to finish my dissertation and helping me to find a post-doctoral position. Lastly, I would like to thank the members of the Klionsky laboratory. It has been a pleasure working and learning with all of you over the last several years. I would especially like to thank Clinton Bartholomew who was always there to offer help and advice when I needed it most, Steven Backues who aided me in my post doctoral search, and Katie Parzych, who was my writing buddy as I put this dissertation together and who didn’t think it strange when I would be “gaily tripping” throughout the lab. iii Chapter 2 is a review article that I authored on the cytoplasm to vacuole targeting pathway: Melinda A. Lynch-Day and Daniel J. Klionsky. The Cvt pathway as a model for selective autophagy. FEBS Letters, 584: 1359-1366, 2010. It has been reprinted here with permission from Elsevier with minor modifications. Chapter 3 is a primary research article that I co-first authored on the role of Trs85 and Ypt1 in autophagy: Melinda A. Lynch-Day, Deepali Bhandari, Shekar Menon, Ju Huang, Huaqing Cai, Clinton R. Bartholomew, John H. Brumell, Susan Ferro-Novick, and Daniel J. Klionsky. Trs85 directs a Ypt1 GEF, TRAPPIII, to the phagophore to promote autophagy. Proc Natl Acad Sci USA, 107: 7811-7816, 2010. It has been reprinted here with permission. I was responsible for figures 3.3, 3.4, 3.5, 3.6, S3.5, S3.6, S3.7, and S3.8B and Table S3.1. Chapter 4 is a manuscript that has been submitted to Science. I was responsible for all of the yeast work in the paper. Chapter 5 is a first author manuscript that has been submitted to Science. I was responsible for all of the figures. Appendix A is a review article that I first authored on the role of autophagy in Parkinson’s Disease: Melinda A. Lynch-Day, Kai Mao, Ke Wang, Mantong Zhao, and Daniel J. Klionsky. The role of autophagy in Parkinson’s disease. Cold Spring Harb Perspect Med, 2: a009357, 2012. It has been reprinted here with permission from Cold Spring Harbor with minor modifications. I was responsible for the writing of the section “Early discoveries: α-SYNUCLEIN and autophagy”, the organization of the section “Recent studies: controversies abound”, and general editing. iv Appendix B is a research study on mitophagy: Tomotake Kanki, Ke Wang, Misuzu Baba, Clinton R. Bartholomew, Melinda A. Lynch-Day, Zhou Du, Kai Mao, Zhifen Yang, Wei-Lien Yen, and Daniel J. Klionsky. A genomic screen for yeast mutants defective in selective mitochondria autophagy. Mol Biol Cell, 20:4730-4738, 2009. It has been reprinted here with permission from The American Society for Cell Biology. I was responsible for the screening of mitophagy defective mutants for defects in the Cvt pathway (Ape1 maturation) and non-specific autophagy (GFP-Atg8 cleavage), figures SB.2B and SB.4. Appendix C is a research study on the transcriptional inhibition of ATG8: Clinton R. Bartholomew, Tsukasa Suzuki, Zhou Du, Steven K. Backues, Meiyan Jin, Melinda A. Lynch-Day, Midori Umekawa, Avani Kamath, Mantong Zhao, Zhiping Xie, Ken Inoki, and Daniel J. Klionsky. Ume6 transcription factor is part of a signaling cascade that regulates autophagy. Proc Natl Acad Sci USA, 2012. It has been reprinted here with permission. I was responsible for figure C.2. v Table of Contents Dedication ........................................................................................................................... ii Acknowledgements ............................................................................................................ iii List of Tables .................................................................................................................... vii List of Figures .................................................................................................................. viii List of Appendices ............................................................................................................. xi CHAPTER 1. The study of autophagy is important for understanding human disease ............1 2. The Cvt pathway as a model for selective autophagy ......................................41 3. Trs85 directs a Ypt1 GEF, TRAPPIII, to the phagophore to promote autophagy .........................................................................................................75 4. The histone acetyltransferase hMOF regulates the outcome of autophagy ...118 5. Histone acetylation regulates autophagy by controlling Atg8 expression .....155 6. Summary and Perspectives ............................................................................188 Appendices .......................................................................................................................205 vi List of Tables Table S3.1. Summary of localization data .....................................................................104 S3.2. Strains .........................................................................................................112 S4.1. Primary antibodies used in this study .........................................................149 S4.2. Reagents used in this study .........................................................................149 S4.3. ON-TARGET plus SMART pool small interfering RNAs used in this study ..............................................................................................................................150 S5.1. Strains .........................................................................................................181 SB.1 Strains used in this study .............................................................................241 SB.2 Initial screen results for all strains tested ....................................................255 SB.3 Summary of autophagy analyses.................................................................259 SC.1 Strains used in this study .............................................................................313 vii List of Figures Figure 2.1. Three main types of autophagy .......................................................................43 2.2. Classification of Atg protein according to function ........................................52 2.3. Cvt vesicle formation ......................................................................................59 3.1. Trs85 does not coprecipitate with Trs130, Trs120, and Trs65 .......................82 S3.1. Epitope tagging Trs85 does not interfere with autophagy function .............83 3.2. Identification of a third TRAPP complex that activates Ypt1 ........................86 S3.2. Trs85 is not a component of the TRAPPI complex ......................................87 S3.3. Loss of Trs85 does not block ER-Golgi traffic ............................................88 S3.4. Subunit composition of the three TRAPPI complex ....................................89 3.3. Ypt1 is involved in nonspecific autophagy in yeast .......................................92 S3.5. Ypt1 is involved in nonspecific autophagy in yeast .....................................93 S3.6. Ypt1 and Trs85 function at the stage of autophagosome formation .............95 3.4. The ypt1 mutants are defective for the Cvt pathway ......................................97 3.5. Ypt1 overexpression enhances autophagy and constitutively active Ypt1 bypasses the requirement for its GEF ....................................................................99 3.6. Ypt1 and Trs85 localize to the PAS ..............................................................103 S3.7. The GFP tag on Trs85 does not result in aggregate formation ...................105 S3.8. Subcellular fractionation and localization of Trs85 ....................................106 4.1. SIRT1-dependent and –independent autophagy is associated with a reduced acetylation of histone H4 lysine 16 ......................................................................125 viii S4.1. Starvation does not induce H4K16ac downregulation in Sirt1-/- MEF cells ......................................................................................................................126
Recommended publications
  • The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy

    The Role of Z-Disc Proteins in Myopathy and Cardiomyopathy

    International Journal of Molecular Sciences Review The Role of Z-disc Proteins in Myopathy and Cardiomyopathy Kirsty Wadmore 1,†, Amar J. Azad 1,† and Katja Gehmlich 1,2,* 1 Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK; [email protected] (K.W.); [email protected] (A.J.A.) 2 Division of Cardiovascular Medicine, Radcliffe Department of Medicine and British Heart Foundation Centre of Research Excellence Oxford, University of Oxford, Oxford OX3 9DU, UK * Correspondence: [email protected]; Tel.: +44-121-414-8259 † These authors contributed equally. Abstract: The Z-disc acts as a protein-rich structure to tether thin filament in the contractile units, the sarcomeres, of striated muscle cells. Proteins found in the Z-disc are integral for maintaining the architecture of the sarcomere. They also enable it to function as a (bio-mechanical) signalling hub. Numerous proteins interact in the Z-disc to facilitate force transduction and intracellular signalling in both cardiac and skeletal muscle. This review will focus on six key Z-disc proteins: α-actinin 2, filamin C, myopalladin, myotilin, telethonin and Z-disc alternatively spliced PDZ-motif (ZASP), which have all been linked to myopathies and cardiomyopathies. We will summarise pathogenic variants identified in the six genes coding for these proteins and look at their involvement in myopathy and cardiomyopathy. Listing the Minor Allele Frequency (MAF) of these variants in the Genome Aggregation Database (GnomAD) version 3.1 will help to critically re-evaluate pathogenicity based on variant frequency in normal population cohorts.
  • SYMPOSIUM References 1

    SYMPOSIUM References 1

    J Orthopaed Traumatol (2008): 24 November 2008 DOI 10.1007/s10195-008-0030-6 24 NOVEMBER 2008 SYMPOSIUM References 1. Pola E, Lattanzi W, Pecorini G, Logroscino CA, Robbins PD (2005) Gene therapy for in vivo bone formation: recent TISSUE ENGINEERING advances. Eur Rev Med Pharmacol Sci 9(3):167–174 2. Pola E, Gao W, Zhou Y, Pola R, Lattanzi W, Sfeir C, et al (2004) A CLINICALLY RELEVANT GENE THERAPY APPROACH Efficient bone formation by gene transfer of human LIM miner- TO INDUCE OSTEOGENESIS: STUDY OF THE NEW alization protein-3. Gene Ther 11(8):683 –693 GROWTH FACTOR LIM MINERALIZAZION PROTEIN-3 3. Lattanzi W, Parrilla C, Fetoni A, Logroscino G, Straface G, Pecorini G, Tampieri A, Bedini R, Pecci R, Michetti F, E. Pola Gambotto A, Robbins PD, Pola E (2008) Ex-vivo transduced autologous skin fibroblasts expressing human Lim Minera - Department of Orthopaedics and Traumatology, Università lization Protein-3 efficiently form new bone in animal models. Cattolica del Sacro Cuore, School of Medicine (Rome-IT) Gene Therapy [Epub ahead of print] Recombinant proteins, such as the bone morphogenetic proteins have been used to enhance repair of non-union fractures and facil- TYPE-I COLLAGEN MEMBRANE AS A SCAFFOLD FOR itate new bone formation in animal models as well as in clinical TENDON REPAIR: AN IN VITRO AND IN VIVO STUDY applications. However, a significant amount of recombinant BMP is required to promote osteogenesis and frequently the extent of A. Gigante, E. Cesari, A. Busilacchi, S. Manzotti, F. Greco new bone formation is low. In contrast, local gene transfer of BMPs has been shown to be more efficient in promoting osteogenesis in Department of Orthopaedics, Polytechnic University of Marche rodents than the use of recombinant proteins.
  • Myosin Binding Protein H-Like (MYBPHL): a Promising Biomarker

    Myosin Binding Protein H-Like (MYBPHL): a Promising Biomarker

    www.nature.com/scientificreports OPEN Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage Received: 8 March 2019 Harald Lahm1, Martina Dreßen1, Nicole Beck1, Stefanie Doppler1, Marcus-André Deutsch2, Accepted: 20 June 2019 Shunsuke Matsushima1, Irina Neb1, Karl Christian König1, Konstantinos Sideris1, Published: xx xx xxxx Stefanie Voss1, Lena Eschenbach1, Nazan Puluca1, Isabel Deisenhofer3, Sophia Doll4, Stefan Holdenrieder5, Matthias Mann 4,6, Rüdiger Lange1,7 & Markus Krane1,7 Myosin binding protein H-like (MYBPHL) is a protein associated with myoflament structures in atrial tissue. The protein exists in two isoforms that share an identical amino acid sequence except for a deletion of 23 amino acids in isoform 2. In this study, MYBPHL was found to be expressed preferentially in atrial tissue. The expression of isoform 2 was almost exclusively restricted to the atria and barely detectable in the ventricle, arteria mammaria interna, and skeletal muscle. After atrial damage induced by cryo- or radiofrequency ablation, MYBPHL was rapidly and specifcally released into the peripheral circulation in a time-dependent manner. The plasma MYBPHL concentration remained substantially elevated up to 24 hours after the arrival of patients at the intensive care unit. In addition, the recorded MYBPHL values were strongly correlated with those of the established biomarker CK-MB. In contrast, an increase in MYBPHL levels was not evident in patients undergoing aortic valve replacement or transcatheter aortic valve implantation. In these patients, the values remained virtually constant and never exceeded the concentration in the plasma of healthy controls. Our fndings suggest that MYBPHL can be used as a precise and reliable biomarker to specifcally predict atrial myocardial damage.
  • Multisystem Myotilinopathy, Including Myopathy and Left Ventricular Noncompaction, Due to the MYOT Variant C.179C>T

    Multisystem Myotilinopathy, Including Myopathy and Left Ventricular Noncompaction, Due to the MYOT Variant C.179C>T

    Hindawi Case Reports in Cardiology Volume 2020, Article ID 5128069, 4 pages https://doi.org/10.1155/2020/5128069 Case Report Multisystem Myotilinopathy, including Myopathy and Left Ventricular Noncompaction, due to the MYOT Variant c.179C>T Josef Finsterer ,1 Claudia Stöllberger,2 Matthias Hasun,2 Korbinian Riedhammer,3,4 and Mathias Wagner3 1Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria 22nd Medical Department with Cardiology and Intensive Care Medicine, Krankenanstalt Rudolfstiftung, Vienna, Austria 3Institute of Human Genetics, Germany 4Department of Nephrology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany Correspondence should be addressed to Josef Finsterer; fi[email protected] Received 21 September 2019; Revised 18 April 2020; Accepted 5 May 2020; Published 14 May 2020 Academic Editor: Kuan-Rau Chiou Copyright © 2020 Josef Finsterer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Left ventricular hypertrabeculation/noncompaction is a myocardial abnormality of unknown etiology/pathogenesis, which is frequently associated with neuromuscular disorders or chromosomal defects. LVHT in association with a MYOT mutation has not been reported. The patient is a 72-year-old male with a history of strabismus in childhood, asymptomatic creatine-kinase elevation since age 42 years, slowly progressive lower limb weakness since age 60 years, slowly progressive dysarthria and dysphagia since age 62 years, and recurrent episodes of arthralgias and myalgias since age 71 years. He also had arterial hypertension, diverticulosis, hyperlipidemia, coronary heart disease, and a hiatal hernia with reflux esophagitis.
  • The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies Review Article

    The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies Review Article

    Review Article 04/25/2018 on mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== by https://journals.lww.com/continuum from Downloaded Downloaded from Address correspondence to https://journals.lww.com/continuum Dr Stanley Jones P. Iyadurai, Ohio State University, Wexner The Limb-Girdle Medical Center, Department of Neurology, 395 W 12th Ave, Columbus, OH 43210, Muscular Dystrophies and [email protected]. Relationship Disclosure: by mAXWo3ZnzwrcFjDdvMDuzVysskaX4mZb8eYMgWVSPGPJOZ9l+mqFwgfuplwVY+jMyQlPQmIFeWtrhxj7jpeO+505hdQh14PDzV4LwkY42MCrzQCKIlw0d1O4YvrWMUvvHuYO4RRbviuuWR5DqyTbTk/icsrdbT0HfRYk7+ZAGvALtKGnuDXDohHaxFFu/7KNo26hIfzU/+BCy16w7w1bDw== Dr Iyadurai has received the Dystrophinopathies personal compensation for serving on the advisory boards of Allergan; Alnylam Stanley Jones P. Iyadurai, MSc, PhD, MD; John T. Kissel, MD, FAAN Pharmaceuticals, Inc; CSL Behring; and Pfizer, Inc. Dr Kissel has received personal ABSTRACT compensation for serving on a consulting board of AveXis, Purpose of Review: The classic approach to identifying and accurately diagnosing limb- Inc; as journal editor of Muscle girdle muscular dystrophies (LGMDs) relied heavily on phenotypic characterization and & Nerve; and as a consultant ancillary studies including muscle biopsy. Because of rapid advances in genetic sequencing for Novartis AG. Dr Kissel has received research/grant methodologies,
  • Arnau Soler2019.Pdf

    Arnau Soler2019.Pdf

    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Genetic responses to environmental stress underlying major depressive disorder Aleix Arnau Soler Doctor of Philosophy The University of Edinburgh 2019 Declaration I hereby declare that this thesis has been composed by myself and that the work presented within has not been submitted for any other degree or professional qualification. I confirm that the work submitted is my own, except where work which has formed part of jointly-authored publications has been included. My contribution and those of the other authors to this work are indicated below. I confirm that appropriate credit has been given within this thesis where reference has been made to the work of others. I composed this thesis under guidance of Dr. Pippa Thomson. Chapter 2 has been published in PLOS ONE and is attached in the Appendix A, chapter 4 and chapter 5 are published in Translational Psychiatry and are attached in the Appendix C and D, and I expect to submit chapter 6 as a manuscript for publication.
  • Characterization of the Dysferlin Protein and Its Binding Partners Reveals Rational Design for Therapeutic Strategies for the Treatment of Dysferlinopathies

    Characterization of the Dysferlin Protein and Its Binding Partners Reveals Rational Design for Therapeutic Strategies for the Treatment of Dysferlinopathies

    Characterization of the dysferlin protein and its binding partners reveals rational design for therapeutic strategies for the treatment of dysferlinopathies Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Sabrina Di Fulvio von Montreal (CAN) Basel, 2013 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Michael Sinnreich Prof. Dr. Martin Spiess Prof. Dr. Markus Rüegg Basel, den 17. SeptemBer 2013 ___________________________________ Prof. Dr. Jörg SchiBler Dekan Acknowledgements I would like to express my gratitude to Professor Michael Sinnreich for giving me the opportunity to work on this exciting project in his lab, for his continuous support and guidance, for sharing his enthusiasm for science and for many stimulating conversations. Many thanks to Professors Martin Spiess and Markus Rüegg for their critical feedback, guidance and helpful discussions. Special thanks go to Dr Bilal Azakir for his guidance and mentorship throughout this thesis, for providing his experience, advice and support. I would also like to express my gratitude towards past and present laB members for creating a stimulating and enjoyaBle work environment, for sharing their support, discussions, technical experiences and for many great laughs: Dr Jon Ashley, Dr Bilal Azakir, Marielle Brockhoff, Dr Perrine Castets, Beat Erne, Ruben Herrendorff, Frances Kern, Dr Jochen Kinter, Dr Maddalena Lino, Dr San Pun and Dr Tatiana Wiktorowitz. A special thank you to Dr Tatiana Wiktorowicz, Dr Perrine Castets, Katherine Starr and Professor Michael Sinnreich for their untiring help during the writing of this thesis. Many thanks to all the professors, researchers, students and employees of the Pharmazentrum and Biozentrum, notaBly those of the seventh floor, and of the DBM for their willingness to impart their knowledge, ideas and technical expertise.
  • Myotilin (MYOT) Mouse Monoclonal Antibody [Clone ID: OTI8A7] Product Data

    Myotilin (MYOT) Mouse Monoclonal Antibody [Clone ID: OTI8A7] Product Data

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA809549 Myotilin (MYOT) Mouse Monoclonal Antibody [Clone ID: OTI8A7] Product data: Product Type: Primary Antibodies Clone Name: OTI8A7 Applications: WB Recommended Dilution: WB 1:2000 Reactivity: Human, Mouse, Rat Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Full length human recombinant protein of human MYOT (NP_006781) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Gene Name: myotilin Database Link: NP_006781 Entrez Gene 9499 Human Q9UBF9 Background: This gene encodes a cystoskeletal protein which plays a significant role in the stability of thin filaments during muscle contraction. This protein binds F-actin, crosslinks actin filaments, and prevents latrunculin A-induced filament disassembly. Mutations in this gene have been associated with limb-girdle muscular dystrophy and myofibrillar myopathies. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been determined. [provided by RefSeq, Oct 2008] Synonyms: LGMD1; LGMD1A; MFM3; TTID; TTOD This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Myotilin (MYOT) Mouse Monoclonal Antibody [Clone ID: OTI8A7] – TA809549 Product images: HEK293T cells were transfected with the pCMV6- ENTRY control (Left lane) or pCMV6-ENTRY MYOT ([RC202797], Right lane) cDNA for 48 hrs and lysed.
  • Variable Gearing in Pennate Muscles

    Variable Gearing in Pennate Muscles

    Variable gearing in pennate muscles Emanuel Azizi*, Elizabeth L. Brainerd, and Thomas J. Roberts Department of Ecology and Evolutionary Biology, Brown University, Providence, RI 02912 Edited by Ewald R. Weibel, University of Bern, Bern, Switzerland, and approved December 3, 2007 (received for review September 27, 2007) Muscle fiber architecture, i.e., the physical arrangement of fibers within a muscle, is an important determinant of a muscle’s me- chanical function. In pennate muscles, fibers are oriented at an angle to the muscle’s line of action and rotate as they shorten, becoming more oblique such that the fraction of force directed along the muscle’s line of action decreases throughout a contrac- tion. Fiber rotation decreases a muscle’s output force but increases output velocity by allowing the muscle to function at a higher gear ratio (muscle velocity/fiber velocity). The magnitude of fiber rota- tion, and therefore gear ratio, depends on how the muscle changes shape in the dimensions orthogonal to the muscle’s line of action. Here, we show that gear ratio is not fixed for a given muscle but decreases significantly with the force of contraction (P < 0.0001). We find that dynamic muscle-shape changes promote fiber rota- tion at low forces and resist fiber rotation at high forces. As a result, gearing varies automatically with the load, to favor velocity output during low-load contractions and force output for contractions against high loads. Therefore, muscle-shape changes act as an automatic transmission system allowing a pennate muscle to shift Fig. 1. A 17th century geometric examination of muscle architecture (5).
  • Exome Sequencing Identifies a Novel TTN Mutation in a Family

    Exome Sequencing Identifies a Novel TTN Mutation in a Family

    Journal of Human Genetics (2013) 58, 259–266 & 2013 The Japan Society of Human Genetics All rights reserved 1434-5161/13 www.nature.com/jhg ORIGINAL ARTICLE Exome sequencing identifies a novel TTN mutation in a family with hereditary myopathy with early respiratory failure Rumiko Izumi1,2, Tetsuya Niihori1, Yoko Aoki1, Naoki Suzuki2, Masaaki Kato2, Hitoshi Warita2, Toshiaki Takahashi3, Maki Tateyama2, Takeshi Nagashima4, Ryo Funayama4, Koji Abe5, Keiko Nakayama4, Masashi Aoki2 and Yoichi Matsubara1 Myofibrillar myopathy (MFM) is a group of chronic muscular disorders that show the focal dissolution of myofibrils and accumulation of degradation products. The major genetic basis of MFMs is unknown. In 1993, our group reported a Japanese family with dominantly inherited cytoplasmic body myopathy, which is now included in MFM, characterized by late-onset chronic progressive distal muscle weakness and early respiratory failure. In this study, we performed linkage analysis and exome sequencing on these patients and identified a novel c.90263G4TmutationintheTTN gene (NM_001256850). During the course of our study, another groups reported three mutations in TTN in patients with hereditary myopathy with early respiratory failure (HMERF, MIM #603689), which is characterized by overlapping pathologic findings with MFMs. Our patients were clinically compatible with HMERF. The mutation identified in this study and the three mutations in patients with HMERF were located on the A-band domain of titin, suggesting a strong relationship between mutations in the A-band domain of titin and HMERF. Mutation screening of TTN has been rarely carried out because of its huge size, consisting of 363 exons. It is possible that focused analysis of TTN may detect more mutations in patients with MFMs, especially in those with early respiratory failure.
  • WO 2011/084768 Al

    WO 2011/084768 Al

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . ... _ . 14 July 2011 (14.07.2011) WO 2011/084768 Al (51) International Patent Classification: Ridge, Loveland, OH 45 140 (US). ARONHALT, Tay¬ A61B 17/00 (2006.01) A61B 19/10 (2006.01) lor, W. [US/US]; 306 Beech Road, Loveland, OH 45140 (US). (21) International Application Number: PCT/US20 10/06 1422 (74) Agents: JOHNSON, Philip, S. et al; Johnson & John son, 1 Johnson & Johnson Plaza, New Brunswick, NJ (22) International Filing Date: 08933 (US). 2 1 December 2010 (21 .12.2010) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Langi English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 61/288,375 2 1 December 2009 (21 .12.2009) US HN, HR, HU, ID, JL, IN, IS, JP, KE, KG, KM, KN, KP, 12/971,249 17 December 2010 (17.12.2010) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicant (for all designated States except US): ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, ETHICON ENDO-SURGERY, INC. [US/US]; 4545 NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, Creek Road, Cincinnati, OH 45242 (US).
  • MYOT Polyclonal Antibody

    MYOT Polyclonal Antibody

    For Research Use Only MYOT Polyclonal antibody Catalog Number:10731-1-AP 4 Publications www.ptgcn.com Catalog Number: GenBank Accession Number: Recommended Dilutions: Basic Information 10731-1-AP BC005376 WB 1:2000-1:10000 Size: GeneID (NCBI): IHC 1:50-1:500 450 μg/ml 9499 Source: Full Name: Rabbit myotilin Isotype: Calculated MW: IgG 55 kDa Purification Method: Observed MW: Antigen affinity purification 55-57 kDa, 35 kDa Immunogen Catalog Number: AG1112 Applications Tested Applications: Positive Controls: IHC, WB, ELISA WB : mouse skeletal muscle tissue; mouse heart tissue Cited Applications: IHC : mouse skeletal muscle tissue; IF, IHC, WB Species Specificity: human, mouse, rat Cited Species: human Note-IHC: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 MYOT (myotilin) is a structural protein of the striated muscle Z-discs. It interacts with both actinin and filamin, Background Information forming a complex to maintain structural stability of muscles. In adult tissues, myotilin is mainly expressed in skeletal and cardiac muscles and in the peripheral nerves. Missense mutations of myotilin cause limb girdle muscular dystrophy 1A and some other myopathy. Two isoforms of MYOT exist due to the alternative splicing. This antibody can detect both of isoforms around 57 kDa and 35 kDa. Notable Publications Author Pubmed ID Journal Application Anna Vihola 31192305 Neurol Genet Marco Savarese 30900782 Ann Neurol IF Roula Ghaoui 26718575 Neurology IHC Storage: Storage Store at -20ºC. Stable for one year after shipment. Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.